Medincell S.A.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
F6104D107
SEDOL
N/A
CIK
N/A
www.medincell.com
LEI:
©
FIGI: BBG00M0C8GJ0
MEDCL
Medincell S.A.
GICS: - · Sector: - · Sub-Sector: -
NAME
Medincell S.A.
ISIN
FR0004065605
TICKER
MEDCL
MIC
XPAR
REUTERS
MEDCL.PA
BLOOMBERG
MEDCL FP
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Wed, 06.11.2024       Medincell
FR0004065605

ACCESS HERE THE COMPLETE PRESS RELEASE Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today as part of its Q3 2024 results, the following information: About UZEDY® Updated 2024 Revenue Outlook: Increased from $80 million to $100 million U.S. Revenues Year-to-Date 2024: $75 million U.S. Revenues for Q3 2024: $35 million M...
Read More
Medincell
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       Medincell
FR0004065605

Medincell (Paris:MEDCL): ACCESS HERE THE COMPLETE PRESS RELEASE TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia. Findings demonstrate significant improvement in soci...
Read More
Medincell
Technical Analysis Termsheet Terminal
Permalink
Mon, 23.09.2024       Medincell
FR0004065605

New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified. Perseris manufacturer announced in July 2024 the discontinuation of its commercial...
Read More
Medincell
Technical Analysis Termsheet Terminal
Permalink
Mon, 23.09.2024       Medincell
FR0004065605

Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘749 / mdc-TJK) in adult patients diagnosed with schizophrenia. Richard Malamut, Chief Medical Officer of Medincell, said: “In addition to publishing the positive efficacy results for the primary and seconda...
Read More
Medincell
Technical Analysis Termsheet Terminal
Permalink
Thu, 05.09.2024       Medincell
FR0004065605

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22nd Annual Global Healthcare Conference held yesterday that c.99% of the targeted injections for submission have been performed as of today (replay available here). Teva also confirmed that the full submission safety results a...
Read More
Medincell
Technical Analysis Termsheet Terminal
Permalink
Tue, 03.09.2024       Medincell
FR0004065605

Collaboration with AbbVie Initiation of preclinical and supportive CMC* work to advance LAI candidate into clinical development Collaboration with Teva UZEDY® (risperidone LAI) Reaffirming revenue guidance for 2024 by Teva: c.$80 million Exploring an additional indication for the treatment of Bipolar I Disorder in adults Olanza...
Read More
Medincell
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements